--- title: "Oleg I Krijanovski, M.D., Ph.D. | Sutter Health" url: "https://www.sutterhealth.org/research/investigators/oleg-i-krijanovski-md-phd-1049681130" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Investigators](https://www.sutterhealth.org/research/investigators) / 4. Oleg I Krijanovski, M.D., Ph.D. ![Oleg I Krijanovski, M.D., Ph.D.](https://dyn.mktgcdn.com/p/oWPJWgCboUxqZApvrWha8T3bs6ZyRlMgoWXo_AiO4GI/fit=crop,gravity=auto,dpr=2,width=240,height=240) # Oleg I Krijanovski, M.D., Ph.D. Investigator [View profile](https://www.sutterhealth.org/find-provider/dr-oleg-i-krijanovski-1046241370) Dr. Oleg I. Krijanovski is a board‑certified medical oncologist and hematologist with more than three decades of clinical, academic, and research experience spanning the United States and internationally. He currently serves as the Medical Director of the Malignant Hematology and Blood & Marrow Transplantation Program at Alta Bates Summit Medical Center in Berkeley, California. Trained in Russia, Vienna, and the University of Michigan, Dr. Krijanovski has extensive expertise in bone marrow transplantation, graft‑versus‑host disease, and hematologic malignancies. His career includes leadership roles in pediatric and adult transplant programs and principal investigator positions on numerous national and international clinical trials. A widely published researcher, he has contributed to advancements in GVHD biomarkers, transplant immunology, and conditioning regimens. Dr. Krijanovski is also an active educator, lecturer, and consultant to leading pharmaceutical organizations, recognized for his lifelong commitment to improving outcomes for patients with complex blood disorders. ## Research studies - Research study ### [Bone Marrow Transplant Database](https://www.sutterhealth.org/research/studies/bone-marrow-transplant-1049141785) Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries ## Clinical trials - Clinical trial ### [Adjuvant Large B-Cell Lymphoma Alpha3](https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994) A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma **Status:** Open to Enrollment - Clinical trial ### [Adverse Effects of Chemotherapy Shengbai Solution](https://www.sutterhealth.org/research/clinical-trials/adverse-effects-of-chemotherapy-shengbai-solution-1097505286) A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy **Status:** Open to Enrollment - Clinical trial ### [Lymphoma, Large B-Cell, Diffuse Expanded Access For Subjects Receiving Lisocabtagen Maraleucel JCAR017-EAP-001](https://www.sutterhealth.org/research/clinical-trials/lymphoma-large-b-cell-diffuse-expanded-access-for-subjects-receiving-lisocabtagen-maraleucel-jcar017-eap-001-2062976151) Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release (JCAR017-EAP-001) **Status:** Open to Enrollment - Clinical trial ### [Multiple Myeloma Expanded Access to Ciltacabtagene Autoleucel (Cilta-Cel) 68284528MMY4006](https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446) Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma **Status:** Open to Enrollment - Clinical trial ### [Multiple Myeloma Expanded Access to Idecabtagene Vicleucel BB2121-EAP-001](https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-idecabtagene-vicleucel-bb2121-eap-001-2062975937) Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release **Status:** Coming Soon Page 1 of 2 ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/investigators/oleg-i-krijanovski-md-phd-1049681130#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Investigators","item":"https://www.sutterhealth.org/research/investigators"},{"@type":"ListItem","position":4,"name":"Oleg I Krijanovski, M.D., Ph.D."}]} ``` ```json {"@context":"https://schema.org","@type":"ProfilePage","@id":"https://www.sutterhealth.org/research/investigators/oleg-i-krijanovski-md-phd-1049681130#profilepage","url":"https://www.sutterhealth.org/research/investigators/oleg-i-krijanovski-md-phd-1049681130","name":"Oleg I Krijanovski, M.D., Ph.D.","dateModified":"2026-06-04","breadcrumb":{"@id":"https://www.sutterhealth.org/research/investigators/oleg-i-krijanovski-md-phd-1049681130#breadcrumblist"},"primaryImageOfPage":{"@type":"ImageObject","contentUrl":"https://a.mktgcdn.com/p/oWPJWgCboUxqZApvrWha8T3bs6ZyRlMgoWXo_AiO4GI/480x480.jpg","width":480,"height":480},"mainEntity":{"@id":"https://www.sutterhealth.org/research/investigators/oleg-i-krijanovski-md-phd-1049681130"}} ``` ```json {"@context":"https://schema.org","@type":"Person","@id":"https://www.sutterhealth.org/research/investigators/oleg-i-krijanovski-md-phd-1049681130","name":"Oleg I Krijanovski, M.D., Ph.D.","givenName":"Oleg","additionalName":"I","familyName":"Krijanovski","honorificSuffix":"M.D., Ph.D.","description":"Dr. Oleg I. Krijanovski is a board‑certified medical oncologist and hematologist with more than three decades of clinical, academic, and research experience spanning the United States and internationally. He currently serves as the Medical Director of the Malignant Hematology and Blood & Marrow Transplantation Program at Alta Bates Summit Medical Center in Berkeley, California. Trained in Russia, Vienna, and the University of Michigan, Dr. Krijanovski has extensive expertise in bone marrow transplantation, graft‑versus‑host disease, and hematologic malignancies. His career includes leadership roles in pediatric and adult transplant programs and principal investigator positions on numerous national and international clinical trials. A widely published researcher, he has contributed to advancements in GVHD biomarkers, transplant immunology, and conditioning regimens. Dr. Krijanovski is also an active educator, lecturer, and consultant to leading pharmaceutical organizations, recognized for his lifelong commitment to improving outcomes for patients with complex blood disorders.","image":{"@type":"ImageObject","contentUrl":"https://a.mktgcdn.com/p/oWPJWgCboUxqZApvrWha8T3bs6ZyRlMgoWXo_AiO4GI/480x480.jpg","representativeOfPage":true},"affiliation":{"@id":"https://www.sutterhealth.org/#medicalorganization"},"mainEntityOfPage":{"@id":"https://www.sutterhealth.org/research/investigators/oleg-i-krijanovski-md-phd-1049681130#profilepage"},"sameAs":"https://www.sutterhealth.org/find-provider/dr-oleg-i-krijanovski-1046241370"} ```